Abstract
The TNM staging classification is the strongest determinate of outcome in patients with non-small cell lung cancer (NSCLC); as a result, it is used to guide treatment decisions (see Chap. 16). Only those patients who undergo complete resection or are treated aggressively with combined modality therapy have the potential for long-term survival. However, even with stage IA tumors, the 5-year survival rate after resection is only 67% (Mountain 1997; Kwiatkowski et al. 1998), indicating that a significant proportion of patients with resectable disease have virulent tumors. The range of survival potentials within each stage underscores the heterogeneous nature of the disease. This has led to the study of other prognostic variables that might complement stage, and to a search for tissue-based, as well as noninvasive, methods for better predicting prognosis and guiding treatment choice (Pugsley et al. 2002; Sorensen 1994).By refining the prognostic assessment of a given patient within (or potentially across) stage subgroups, a better tailored therapy might be feasible.
Keywords
- Lung Cancer
- Cell Lung Cancer
- Proliferate Cell Nuclear Antigen
- Small Cell Lung Cancer
- Small Cell Lung Carcinoma
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsPreview
Unable to display preview. Download preview PDF.
References
Ahuja V, Coleman RE, Herndon J et al (1998) The prognostic significance of fluorodeoxyglucose positron emission tomography imaging for patients with non-small cell lung carcinoma. Cancer 83:918
Aisner J, Hansen HH (1981) Commentary: current status if chemotherapy for NSCLC. Cancer Treat Rep 65: 979
Alama A, Constantini M, Repetto L et al (1990) Thymidine labeling index as prognostic factor in resected non-small cell lung cancer. Eur J Cancer 26:622
Albain KS, Crowley JJ, LeBlanc M et al (1991) Survival determinants in extensive stage non-small cell lung cancer: the Southwest Oncology Group experience. J Clin Oncol 9:1618
Al-Kattan K, Sepsas E, Townsend E et al (1996) Factors affecting long-term survival following resection for lung cancer. Thorax 51:1266
Andre F, Grunenwald D, Pignon JP et al (2000) Survival of patients with resected N2 non-small cell lung cancer: evidence for a subclassification and implications. J Clin Oncol 18:2981
Apolinario RM, van der Valk P, de Jong JS et al (1997) Prognostic value of the expression of p53, bcl-2 and bax oncoproteins and neovascularization in patients with radically resected nonsmall cell lung cancer. J Clin Oncol 15:2456
Battifora H, Sorensen HR, Mehta P et al (1992) Tumor-associated antigen 43-9F is of prognostic value in squamous cell carcinoma of the lung. Cancer 70:1867
Berendsen HH, de Leij L, Poppema S et al (1989) Clinical characterization of non-small cell lung cancer tumors showing neuroendocrine differentiation features. J Clin Oncol 7:1614
Bernet F, Brodbeck R, Guenin MO et al (2000) Age does not influence early and late tumor-related outcome for bronchogenic carcinoma. Ann Thorac Surg 69:913
Blackstock AW, Herndon JE 2nd, Paskett ED et al (2002) 0utcomes among African-American/non-African-American patients with advanced non-small-cell lung carcinoma: report from the Cancer and Leukemia Group B. J Natl Cancer Inst 94:284
Bonomi P (2002) Matrix metalloproteinases and matrix metalloproteinase inhibitors in lung cancer. Semin Oncol 29 [Suppl 4]:78
Buccheri G, Ferrigno D, Tamburini M (1996) Karnofsky and ECOG Performance status scoring in lung cancer: a prospective, longitudinal study of 536 patients from a single institution. Eur J Cancer 32A:1135
Carbone DP, Mitsudomi T, Chiba I et al (1994) p53 immunostaining positivity is associated with reduced survival and is imperfectly correlated with gene mutations in resected non-small cell lung cancer. A preliminary report of LCSG 871. Chest 106 [Suppl6]:377S
Cattoretti G, Becker MH, Key G et al (1992) Monoclonal antibodies against recombinant parts of the Ki-67 antigen (MIB 1 and MIB 3) detect proliferating cells in microwave-processed formalin-fixed paraffin sections. J Pathol 168:357
Chen CY, Hsu CP, Hsu NY et al (2002) Expression of dihydrodiol dehydrogenase in the resected stage I non-small cell lung cancer. Oncol Rep 9:515
Chiba I, Takahashi T, Nau MM et al (1990) Mutations in the p53 gene are frequent in primary, resected non-small cell lung cancer. Oncogene 5:1603
Cho JY, Kim JH, Lee YH et al (1997) Correlation between K-ras gene mutation and prognosis of patients with non-small cell lung carcinoma. Cancer 79:462
Choma D, Daures JP, Quantin X et al (2001) Aneuploidy and prognosis of non-small cell lung cancer: a meta-analysis of published data. Br J Cancer 85:14
Cote RJ, Beattie EJ, Chaiwun B et al (1995) Detection of occult bone marrow micrometastases in patients with operable lung carcinoma. Ann Surg 222:415
D’Amico TA, Massey M, Herndon JE 2nd et al (1999) A biologic risk model for stage I lung cancer: immunohistochemical analysis of 408 patients with the use of ten molecular markers. J Thorac Cardiovasc Surg 117:736
Deslaurier J, Brisson J, Cartier R et al (1989) Carcinoma of the lung. Evaluation of satellite nodules as a factor in influencing prognosis after resection. J Thorac Cardiovasc Surg 97:504
Dhital K, Saunders CA, Seed PT et al (2000) [(l8)F] Fluorodeoxyglucose positron emission tomography and its prognostic value in lung cancer. Eur J Cardiothorac Surg 18:425
Dresler CN, Ritter JH, Wick MR et al (1995) Immunostains for blood group antigens lack prognostic significance in T1 lung carcinomas. Ann Thorac Surg 59:1069
Duarte I, Buflin BL, Pennington MF et al (1998) Angiogenesis as a predictor of survival after surgical resection for stage I non-small cell lung cancer. J Thorac Cardiovasc Surg 115:652
Duhaylungsod FG, Lowe VJ, Patz EF et al (1995) Lung tumor growth correlates with glucose metabolism measured by fluoride-18 fluorodeoxyglucose positron emission tomography. Ann Thorac Surg 60:1348
Ebina M, Steinberg SM, Mulshine JL et al (1994) Relationship of p53 overexpression and up-regulation of proliferating cell nuclear antigen with the clinical course of non-small cell lung cancer. Cancer Res 54:2496
Feinstein AR (1964) Symptomatic patterns, biologic behavior and prognosis in cancer of the lung. Ann Intern Med 61:27
Feld R, Abratt R, Graziano S et al (1997) Pretreatment minimal staging and prognostic factors for non-small cell lung cancer. Lung Cancer 17 [Suppl 1]:S3
Feld R, Borges M, Giner V et al (1994) Prognostic factors in non-small cell lung cancer. Lung Cancer 11 [Suppl 3]:S19
Ferguson MK, Skosey C, Hoffman PC et al (1990) Sex-associated differences in presentation and survival in patients with lung cancer. J Clin Oncol 8:1402
Finkelstein DM, Ettinger DS, Ruckdeschel JC (1986) Long-term survivors in metastatic non-small-cell lung cancer: an Eastern Cooperative Oncology Group Study. J Clin Oncol 4:702
Fontanini G, DeLaurentiis M, Vignati S et al (1998) Evaluation of epidermal growth factor-related growth factors and receptors and of neoangiogenesis in completely resected stage I-IIIA non-small cell lung cancer:amphiregulin and microvessel count are independent indicators of survival. Clin Cancer Res 4:241
Fontanini G, Lucchi M, Vignati S et al (1997) Angiogenesis as a prognostic indicator of survival in non-small-cell lung carcinoma: a prospective study. J Natl Cancer Inst 89:881
Fontanini G, Vignati S, Bigini JD et al (1995) BCL-2 protein: a prognostic factor inversely correlated to p53 in non-small cell lung cancer. Br J Cancer 71:1003
Fujii M, Motoi M, Saeki H et al (1993) Prognostic significance of proliferating cell nuclear antigen (PCNA) expression in non-small cell lung cancer. Acta Med Okayama 47:103
Gaffney EF, O’Neil AJ, Staunton MJ (1994) bcl-2 and prognosis in non-small-cell lung carcinoma. N Engl J Med 330:1757
Gail M, Eagan RT, Feld R et al (1984) Prognostic factors in patients with resected stage I NSCLC: a report from the Lung Cancer Study Group. Cancer 54:1802
Gerdes J, Lemke H, Baisch H et al (1984) Cell cycle analysis of a cell proliferation-associated human nuclear antigen defined by the monoclonal antibody Ki-67. J Immunol 133:1710
Giatromanolaki A, Gorgiulis V, Chetty R et al (1996) C-ERB B-2 oncoprotein expression in operable non-small cell lung cancer. Anticancer Res 16:987
Ginsberg RJ, Rubinstein LV (1995) Randomized trial of lobectomy versus limited resection for T1 NO non-small cell lung cancer. Lung Cancer Study Group. Ann Thorac Surg 60:615
Graziano SL (1997) Non-small cell lung cancer: clinical value of new biological predictors. Lung Cancer 17 [Suppl 1]:S37
Graziano SL, Mazid R, Newman N et al (1989) The use of neuroendocrine immunoperoxidase markers to predict chemotherapy response in patients with non-small cell lung cancer. J Clin Oncol 7:1398
Graziano SL, Tatum AH, Newman NB et al (1994) The prognostic significance of neuroendocrine markers and carcinoembryonic antigen in patients with resected stage I and II non-small cell lung cancer. Cancer Res 54:2908
Graziano SL, Gamble GP, Newman NB et al (1999) The prognostic significance of K-ras codon 12 mutations in patients with resected stage I and II non-small cell lung cancer. I Clin Oncol 17:668
Greatens TM, Niehans GA, Rubins JB et al (1998) Do molecular markers predict survival in non-small cell lung cancer? Am J Respir Crit Care Med 157:1093
Gwin JL, Klein-Szanto AJ, Zhang SY et al (1994) Loss of blood group antigen A in non-small cell lung cancer. Ann Surg Oncol 1:423
Harada M, Dosaka-Akita H, Miyamoto H et al (1992) Prognostic significance of the expression of ras oncogene product in non-small cell lung cancer. Cancer 69:72–77
Harpole DH (1999) Commentary on “Prognostic markers in resected stage I and II non-small cell lung cancer patients”. Clin Lung Cancer 1:68
Harpole DH, Herndone JE, Young WG et al (l995a) Stage I non-small cell lung cancer: a multivariate analysis of treatment methods and patterns of recurrence. Cancer 76:787
Harpole DH, Herndon JE, Wolfe WG et al (l995b) A prognostic model of recurrence and death in stage I non-small cell lung cancer utilizing presentation, histopathology and oncoprotein expression. Cancer Res 55:51
Harpole DH, Richards WG, Herndon JE et al (1996) Angiogenesis and molecular biologic substaging in patients with stage I non-small cell lung cancer. Ann Thorac Surg 61:1470
Higashi K, Veda y, Ayabe K et al (2000) FDG PET in the evaluation of the aggressiveness of pulmonary adenocarcinoma: correlation with histopathological features. Nucl Med Commun 21: 707
Hommura F, Dosaka-Akita H, Mishina T et al (1999) Prognostic significance of p27KIPI protein and ki-67 growth fraction in non-small cell lung cancer. Lung Cancer 24:81
Hsu NY, Ho HC, Chow KC et al (2001) Overexpression of dihydrodiol dehydrogenase as a prognostic marker of non-small cell lung cancer. Cancer Res 61:2727
Icard P, Regnard JF, Essomba A et al (1994) Preoperative carcinoembryonic antigen level as a prognostic indicator in resected primary lung cancer. Ann Thorac Surg 58:811
Ichinose Y, Yano T, Asoh H et al (1995) Prognostic factors obtained by a pathologic examination in completely resected non-small cell lung cancer. J Thorac Cardiovasc Surg 110:601
Inoue T, Ishida T, Sugio K et al (1994) Cathepsin B expression and laminin degradation as factors influencing prognosis of surgically treated patients with lung adenocarcinoma. Cancer Res 54:6133
Ishida T, Kaneko S, Akazawa K et al (1993) Proliferating cell nuclear antigen expression and argyrophilic nucleolar organizer regions as factors influencing prognosis of surgically treated lung cancer patients. Cancer Res 53:5000
Isobe H, Miyamoto H, Shimizu T et al (1990) Prognostic and therapeutic significance of the flow cytometric nuclear DNA content in non-small cell lung cancer. Cancer 65:1391
Izbicki JR, Passlick, Hosch SB et al (1996) Mode of spread in the early phase of lymphatic metastasis in non-small cell lung cancer: significance of nodal micrometastasis. J Thorac Cardiovasc Surg 112:623
Izumi M, Nakanishi Y, Yoshino I et al (2001) Expression of tumorassociated antigen RCASI correlates significantly with poor prognosis in non-small cell lung carcinoma. Cancer 92:446
Jansen RL, Hupperets PS, Arends JW et al (1998) MIB-1 labeling index is an independent prognostic marker in primary breast cancer. Br J Cancer 78:460
Jazieh AR, Hussain Mohammad, Howington JA et al (2000) Prognostic factors in patients with surgically resected stages I and II non-small cell lung cancer. Ann Thorac Surg 70:1168
Kaneko S, Ishida T, Sugio K et al (1991) Nucleolar organizer regions as a prognostic indicator for stage I non-small cell lung cancer. Cancer Res 51:4008
Kern JA, Schwartz DA, Nordberg JE et al (1990) p185neu expression in human lung adenocarcinomas predicts shortened survival. Cancer Res 50:5184–5187
Kessler R, Gasser B, Massard G et al (1996) Blood vessel invasion is a major prognostic factor in resected non-small cell lung cancer. Ann Thorac Surg 62:1489
Kimura Y, Fujii T, Hamamoto K et al (1990) Serum CA 125 level is a good prognostic indicator in lung cancer. Br J Cancer 62:676
Klatersky J, Sculier IP, Bureau G et al (1989) Cisplatin versus cisplatin plus etoposide in the treatment of advanced non-small cell lung cancer. J Clin Oncol 7:1087
Komaki R, Milas L, Ro JY et al (1998) Prognostic biomarker study in pathologically staged N1 non-small cell lung cancer. Int J Radiat Oncol Biol Phys 40:787
Kos J, Sekirnik A, Kopitar G, Cimerman N et al (2001) Cathepsin S in tumours, regional lymph nodes and sera of patients with lung cancer: relation to prognosis. Br J Cancer 85:1193
Kubuschok B, Passlick B, Izbicki JR et al (1999) Disseminated tumor cells in lymph nodes as a determinant for survival in surgically resected non-small-cell lung cancer. J Clin Oncol 17:19
Kwiatkowski DJ Jr, DHH, Godleski J et al (1998) Molecular pathologic substaging in 244 stage I non-small cell lung cancer patients: clinical implications. J Clin Oncol 16:2468
Lanzotti VJ, Thomas DR, Boyle LE et al (1977) Survival with inoperable lung cancer: an integration of prognostic variables based on simple clinical criteria. Cancer 39:303
Lee JS, Ro JY, Sahin AA et al (1991) Expression of blood-group antigen A: a favorable prognostic factor in non-small cell lung cancer. N Engl J Med 324:1084
Linnoila RI, Jensen S, Steinberg S et al (1989) Neuroendocrine differentiation in non-small cell lung cancer correlates with favorable response to chemotherapy. Proc Am Soc 8:248
Linnoila RI, Piantadosi S, Ruckdeschel JC (1994) Impact of neuroendocrine differentiation in non-small cell lung cancer. The LCSG experience. Chest 106:367S
Lipford EH III, Ehhleston JC, Lillemoe KD et al (1984) Prognostic factors in surgically resected limited stage non-small cell carcinoma of the lung. Am J Surg Pathol 8:357
Little AG, Wu HS, Ferguson MK et al (1990) Perioperative blood transfusion adversely affects prognosis of patients with stage I non-small-cell lung cancer. Am J Surg 160:630
Luedke DW, Einhorn L, Omura GA et al (1990) Randomized comparison of two combination regimens versus minimal chemotherapy in non-small cell lung cancer: a Southeastern Cancer Study Group Trial. J Clin Oncol 8:886
Macchiarini P, Fontanini GM, Hardin MJ et al (1992) Relation of neovascul arization to metastasis of non-small cell lung cancer. Lancet 340:145
Macchiarini P, Fontanini G, Hardin MJ et al (1993) Blood vessel invasion by tumor cells predicts recurrence in completely resected TlNOMO non-small cell lung cancer. J Thorac Cardiovase Surg 106:80
Maggi G, Casadio C, Cianci R et al (1993) Results of surgical resection of stage IIIa (N2) non small cell lung cancer, according to the site of the mediastinal metastases. Int Surg 78:213
Mankoff DA, Shields AF, Graham MM et al (1998) Kinetic analysis of 2-[carbo-ll) thymidine PET imaging studies: compartmental model and mathematical analysis. J Nucl Med 39:1043
Martini N, Bains MS, Burt ME et al (1995) Incidence of local recurrence and second primary tumors in resected stage I lung cancer. J Thorac Cardiovasc Surg 109:120
Martini N, Burt M, Bains M et al (1992) Survival after resection of stage II non-small cell lung cancer. Ann Thorac Surg 54:460
Matsumoto H, Muramatsu H, Shimotakahara T et al (1993) Correlation of expression of ABH blood group carbohydrate antigens with metastatic potential in human lung carcinomas. Cancer 72:75
McLaren R, Kuzu I, Dunnill M et al (1992) The relationship of p53 immunostaining to survival in carcinoma of the lung. Br J Cancer 66:735
Mehdi SA, Tatum AH, Newman NB et al (1999) Prognostic markers in resected stage I and II non-small cell lung cancer: an analysiss of 260 patients with 5 year follow-up. Clin Lung Cancer 1:59
Miller TP, Chen TT, Coltman Ca et al (1986) Effect of alternating combination chemotherapy on survival of ambulatory patient s with metastatic large cell and adenocarcinoma of the lung. A Southwest Oncology Group Study. J Clin Oncol 4:502
Mitsudomi T, Steiberg SM, Oie H et al (1991) Ras gene mutations in non-small cell lung cancers are associated with shortened survival irrespective of treatment intent. Cancer Res 51:4999
Mitsudomi T, Steinberg SM, Nau MM et al (1992) p53 gene mutations in non-small cell lung cancer cell lines and their correlation with the presence of ras mutations and clinical features. Oncogene 7:171
Mitsudomi T, Hamajima N, Ogawa M et al (2000) Prognostic significance of p53 alterations in patients with non-small cell lung cancer: a meta-analysis. Clin Cancer Res 6:4055
Miyake M, Taki T, Hitomi S et al (1992) Correlation of expression of H/Ley/Leb antigens with survival in patients with carcinoma of the lung. N Engl J Med 327:14
Mizushima Y, Noto H, Sugiyama S et al (1997) Survival after pneumonectomy for lung patients in the elderly. Ann Thorac Surg 64:93
Molino A, Micciolo R, Turazza M et al (1997) Ki-67 immunostaining in 322 primary breast cancers:associations with clinical and pathological variables and prognosis. Int J Cancer 74:433
Mori M, Kohli A, Baker SP et al (1997) Laminin and cathepsin Bas a prognostic factor in stage I non-small cell lung cancer: are they useful? Modern Pathol 10:572
Mountain CF (1997) Revisions in the international system for staging lung cancer. Chest 111:1710
Murgueza JM, Diez M, Torres AJ et al (1997) Prognostic value of flow cytometric DNA analysis in non-small cell lung cancer: rationales of sequential processing of frozen and paraffin-embedded tissue. World J Surg 21:323
Nabeshima K, Shimao Y, Inoue T et al (2002) Matrix metalloproteinases (MMP) in lung cancer. Nippon Rinsho 60 [Suppl 5]: 103
Naito T, Satoh H, Ishikawa H et al (1997) Pleural effusion as a significant prognostic factor in non-small cell lung cancer. Anticancer Res 17:4743
Naruke T, Tsuchiya R, Kondo H et al (2001) Prognosis and survival for bronchogenic carcinoma based on the 1997 TNM staging classification: the Japanese experience. Ann Thorac Surg 71:1759
O’Connell JP, Kris MG, Gralla RJ et al (1986) Frequency and prognostic importance of pretreatment clinical characteristics in patients with advanced non-small cell lung cancer treated with combination chemotherapy. J Clin Oncol 4:1604
Ohgami A, Tetsuya M, Kenji S et al (1997) Micrometastatic tumor cells in the bone marrow of patients with non-small cell lung cancer without overt meta stases. Lancet 64:363
Ohsaki Y, Toyoshima E, Fujiuchi S et al (1996) p53 protein expression in non-small cell lung cancers: correlation with survival time. Clin Cancer Res 2:915
Okada M, Tsubota N, Yoshimura M et al (1999) Evaluation of TNM classification for lung carcinoma with ipsilateral intrapulmonary metastasis. Ann Thorac Surg 68:326
Oyama T, Mitsudomi T, Yoshida Y et al (1993) Nucleolar organizer regions are independently associated with a shortened survival in patients with non-small cell lung cancer. Surg Oncol 6:341
Padilla J, Calvo V, Penalver JC et al (1997) Surgical results and prognostic factors in early non-small cell lung cancer. Ann Thorac Surg 63:324
Paesmans M, Sculier JP, Libert P et al (1995) Prognostic factors for survival in advanced non-small cell lung cancer: univariate and multivariate analyses including recursive partitioning and amalgamation algorithms in 1502 patients. J Clin Oncol 13:1221
Pairolero PC, William DE, Bergstralh EJ et al (1984) Postsurgical stage I bronchogenic carcinoma: morbid implications of recurrent disease. Ann Thorac Surg 38:412
Palomares MR, Sayre JW, Shekar KC et al (1996) Gender influence on weight loss pattern and survival of non-small cell lung carcinoma patients. Cancer 78:2119
Pantel K, Izbicki J, Passlick B et al (1996) Frequency and prognostic significance of isolated tumour cells in bone marrow of patients with non-small-cell lung cancer without overt metastases. Lancet 347:649
Pantel K, Passlick B, Vogt J et al (1998) Reduced expression of plakoglobin indicates an unfavorable prognosis in subsets of patients with non-small cell lung cancer. J Clin Oncol 16:1407
Passlick B, Izbicki JR, Kubuschok B (1994) Immunohistochemical assessment of individual tumor cells in the lymph nodes of patients with non-small cell lung cancer. J Clin Oncol 12:1827
Pastorino U, Andreola S, Tagliabue E et al (1977) Immunohistochemical markers in stage I lung cancer: relevance to prognosis. J Clin Oncol 15:2858
Pastorino U, Andreola S, Tagliabue E et al (1997) Immunocytochemical markers in stage I lung cancer: relevance to prognosis. J Clin Oncol 15:2858
Pastorino U, Valente M, Cataldo I (1986) Perioperative blood transfusion and prognosis of resected stage Ia lung cancer. Eur J Cancer Clin Oncol 22:1375
Pelletier MP, Edwardes MD, Michel RP et al (2001) Prognostic markers in resectable non-small cell lung cancer: a multivariate analysis. Can J Surg 44:180
Pena CM, Rice TW, Ahmad M et al (1992) Significance of perioperative blood transfusions in patients undergoing resection of stage I and II non-small-cell lung cancers. Chest 102:84
Pence JC, Kerns BM, Dodge RK et al (1993) Prognostic significance of the proliferation index in surgically resected non-small cell lung cancer. Arch Surg 128:1382
Pezzella F, Turley H, Kuzu I et al (1993) Bcl-2 protein in non-small lung carcinoma. N Engl J Med 329:690
Piantadosi S, Moores DW, McKneally MF (1994) The adverse effect of perioperative blood transfusion in lung cancer. Chest 106 [Suppl6]:382S
Poncelet AJ, Weynand B, Ferdin F (2001) Bone marrow micrornetastas is might not be a short-term predictor of survival in early stages non-small cell lung carcinoma. Eur J Cardio Thorac Surg 20:481
Puglisi F, Aprile G, Bruckbauer M et al (2001) Combined analysis of MIB-1 and thyroid transcription factor-1 predicts survival in non-small cell lung carcinomas. Cancer Lett 162:97
Pugsley JM, Schmidt RA, Vesselle H et al (2002) The Ki-67 Index and Survival in non-small cell lung cancer: a review and relevance to positron emission tomography. Cancer J 8:222
Quinlan DC, Davidson AG, Summers CL et al (1992) Accumulation of p53 protein correlation with a poor prognosis in human lung cancer. Cancer Res 52:4828
Rainio P, Bloigu R, Satta J et al (1996) Ten-year survival after resection for lung carcinoma. Effect of blood transfusion and tumour stage on outcome. Scand J Thorac Cardiovasc Surg 30:87
Rapp E, Pater JL, Willan A et al (1988) Chemotherapy can prolong survival in patients with advanced non-small cell lung cancer — report of a Canadian multicenter randomized trial. J Clin Onco1 6:633
Read RC, Schaefer R, North N et al (1988) Diameter, cell type and survival in stage I primary non-small cell lung cancer. Arch Surg 123:446
Read RC, Yoder G, Schaeffer RC (1990) Survival after conservative resection for T1 NO MO non-small cell lung cancer. Ann Thorae Surg 49:391
Rice TW, Tubbs RR, Hoeltge GA et al (1995) Expression of blood group ant igen A by stage I non-small cell lung carcinomas. Ann Thorac Surg 59:568
Ries LA (1994) Influence of extent of disease, histology and demographic factors on lung cancer survival in the SEER population-based data. Semin Surg Oncol 10:21
Riquet M, Manac′h D, Le Pimpec B (1997) Prognostic value of T and N in non small cell lung cancer three centimeters or less in diameter. Eur J Cardiothorac Surg 11:440
Rodenhuis S, Slebos RJ (1992) Clinical significance of ras oncogene activation in human lung cancer. Cancer Res [Suppl] 52: 2665
Rodenhuis S, Boerrigter L, Top B et al (1997) Mutational activation of the K-ras oncogene and the effect of chemotherapy in advanced adenocarcinoma of the lung: a prospective study. J Clin Onco1 15:285
Rodrigues OR, Antonangelo L, Yagin et al (1997) Prognostic significance of argyrophilic nucleolar organizer region (AgNOR) in resected non-small cell lung cancer (NSCLC). Jpn J Clin Oncol 27:298
Rorke S, Murphy S, Khalifa M et al (2001) Prognostic significance of BAG-I expression in non-small cell lung cancer. Int J Cancer 95:317
Rosell R, Li S, Mate JL et al (1993) A prognostic impact of mutated k-ras gene in surgically resected non-small cell lung cancer patients. Oncogene 8:2407
Rubins JB, Dunitz J, Rubins HB et al (1998) Serum carcinoernbryonic antigen as an adjunct to preoperative staging of lung cancer. J Thorac Cardiovasc Surg 116:412
Rusch VW, Dmitrovsky E (1995) Molecular biologic features of non-small cell lung cancer: clinical implications. Chest Surg Clin North Am 5:39
Sahin AA, Ro JY, El-Naggar AK et al (1990) Flow cytometric analysis of the DNA content of non-small cell lung cancer. Cancer 65:530
Salgia R, Skarin AT (1998) Molecular abnormalities in lung cancer. JCO 16:1207
Schiller JH, Adak S, Feins R et al (1999) Prognostic significance of p53 and K-ras mutations in primary resected non-small cell lung cancer:preliminary results from a prospective randomized trial of postoperative adjuvant therapy (Intergroup Trial 0115). Proc Am Soc Clin Oncol 18:464a (abstract 1789)
Segawa Y, Okahara M et al (1996) Prognostic factors for patients with advanced non-small cell lung cancer: univariate and multivariate analyses including recursive partitioning and amalgamation. Lung Cancer 15:67
Shiba M, Kohno H, Kakizawa K et al (2000) Ki-67 immunostaining and other prognostic factors including tobacco smoking in patients with resected non-small cell lung carcinoma. Cancer 89:1457
Shields AF, Grierson JR, Dohmen BM et al (1998) Imaging proliferat ion in vivo with [F-18] FLT and positron emission tomography. Nat Med 4:1334
Shields TW (1983) Prognostic significance of parenchymal lymphatic vessel and blood vessel invasion in carcinoma of the lung. Surg Gynecol Obstet 157:185
Slebos RJ, Kibbelaar RE, Dalesio O et al (1990) K-ras oncogene activation as a prognostic marker in adenocarcinoma of the lung. N Engl J Med 323:561
Sorensen JB (1994) Impact of prognostics factors on endpoints for clinical studies. Lung Cancer 11 [Suppl 3]:S45
Stanley KE (1980) Prognostic factors for survival in patients with inoperable lung cancer. J Natl Cancer Inst 65:25
Staruss GM (1997) Prognostic markers in respectable non-small cell lung cancer. Hematol/Oncol Clin North Am 1:409
Stevenson H, Gazdar AF, Phelps R (1990) Tumor cell lines established in vitro: an independent prognostic factor for survival in non-small cell lung cancer. Ann Intern Med 113:764
Sugio K, Ishida T, Yokoyama H et al (1992) Ras gene mutations as a prognostic marker in adenocarcinoma of the lung without lymph node metastasis. Cancer Res 52:2903
Sugio K, Tsukamoto S, Ushijima C et al (2001) Clinical significance of the Rb expression in adenocarcinoma of the lung. Anticancer Res 21:1931
Sukoh N, Abe S, Ogura S et al (1994) Immunohistochemical study of cathepsin B. Prognostic significance in human lung cancer. Cancer 74:46
Sulzer MA, Leers MPG, Noord JAV et al (1998) Reduced E-cadherin expression is associated with increased lymph node metastasis and unfavourable prognosis in non-small cell lung cancer. Am J Crit Care Med 157:1319
Suzuki K, Nagai K, Yoshida J et al (1999) Prognostic factors in clinical stage I non-small cell lung cancer. Ann Thorac Surg 67:927
Takise A, Kodama T, Shimosata Y et al (1988) Histopathologic prognostic factors in adenocarcinoma of the peripheral lung less than 2 em in diameter. Cancer 61:2083
Tanaka F, Miyahara R, Ohtake Y et al (1998) Lewis Y antigen expression and postoperative survival in non-small cell lung cancer. Ann Thorac Surg 157:1093
Tartter PI, Burrows L, Kirschner P (1984) Perioperative blood transfusion adversely affects prognosis after resection of Stage I (subset NO) non-oat cell lung cancer. J Thorac Cardiovase Surg 88:659
Tateishi M, Ishida T, Mitsudomi T et al (1991) Prognostic value of c-erbB-2 protein overexpression in human lung adenocarcinoma and squamous cell carcinoma. Eur J Cancer 27:1372
TenVelde GP, Havenith MG, Volovics A et al (1991) Prognostic significance of basement membrane deposition in operable squamous cell carcinomas of the lung. Cancer 67:3001
Thomas P, Doddoli C, Thirion X et al (2002) Stage I non-small cell lung cancer: a pragmatic approach to prognosis after complete resection. Ann Thorac Surg 73:1065
Thomas PA, Piantadosi S (1987) Postoperative T1N0 non-small cell lung cancer: squamous versus nonsquamous recurrences. J Thorac Cardiovasc Surg 94:349
Tisi E, Lissoni P, Angeli M et al (1992) Postoperative increase in soluble interleukin-2 receptor serum levels as predictor for early recurrence in non-small cell lung carcinoma. Cancer 69:2458
Unger JM, Coltman CA, Appelbaum FR et al (2003) African Americans have worse survival in hormone-related cancers. A Southwest Oncology Group Study. Proc Amer Soc Clin Oncol 22:529
Uramoto H, Osaki T, Inoue M et al (1999) Fas expression in non-small cell lung cancer: its prognostic effect in completely resected stage III patients. Eur J Cancer 35:1462
Van Klaveren RJ, Festen J, Otten HJ et al (1993) Prognosis of unsuspected but completely resected N2 non-small cell lung cancer. Ann Thorac Surg 56:300
Van Velzen E, Snijder RJ, Brutel de la Rivieire A et al (1997) Lymph node type as a prognostic factor for survival in T2 Nl M0 non-small cell lung carcinoma. Ann Thorac Surg 63:1436
Vander Borght T, Pauwels S, Lambotte L et al (1994) Brain tumor imaging with PET and 2-[carbon-11] thymidine. J Nuel Med 35:974
Vansteenkiste J, Stroobants SG, Dupont PJ et al (1999) Prognostic importance of standardized uptake value on (18) F-fluoro-2-deoxyglucose-positron emission tomography scan in non-small cell lung cancer: an analysis of 125 cases. Leuven Lung Cancer Group. J Clin Oncol 17:3201
Vesselle H, Schmidt RA, Pugsley JM et al (2000) Lung cancer proliferation correlates with [F-18] fluorodeoxyglucose uptake by positron emission tomography. Clin Cancer Res 6:3837
Volm M, Koomagi R (2000) Prognostic relevance of c-Myc and caspase-3 for patients with non-small cell lung cancer. Oncol Rep 7:95
Volm M, Hahn EW, Mattern J et al (1988) Five-year follow-up study of independent elinical and flow cytometric prognostic factors for the survival of patients with non-small cell lung carcinoma. Cancer Res 48:2923
Volm M, Rittgen W, Drings P (1998) Prognostic value of ERBB-1, VEGF, cyelin A, FOS, JUN and MYC in patients with squamous cell lung carcinomas. Br J Cancer 77:663
Wang Z, Zhao X (1998) Expression and prognostic relation of cathepsin D in non-small cell lung cancer tissues and lymph nodes. Zhonghua Jie He He Hu Xi Za Zhi 21:164
Werle B, Kraft C, Lah TT et al (2000) Cathepsin B in infiltrated lymph nodes is of prognostic significance for patients with non-small cell lung carcinoma. Cancer 89:2282
Wertzel H, Siebert H, LangeW et al (1998) Results after surgery in stage I bronchogenic carcinoma. Thorac Cardiovasc Surg 46:365
Xu HJ, Quinlan DC, Davidson AG et al (1994) Altered retinoblastoma protein expression and prognosis in early stage non-small cell lung carcinoma. J Natl Cancer Inst 86:695
Yano T, Yokoyama H, Inoue T et al (1994) Surgical results and prognostic factors of pathologic N1 disease in non-small cell carcinoma of the lung. Significance of Nl level: Lobar or hilar nodes. J Thorac Cardiovasc Surg 107:1398
Ylisirnio S, Hoyhtya M, Makitaro R et al (2001) Elevated serum levels of type I collagen degradation marker ICTP and tissue inhibitor of metalloproteinase (TIMP) 1 are associated with poor prognosis in lung cancer. Clin Cancer Res 7:1633
Yu C, Shun C, Yang P et al (1997) Sialomucin expression is associated with erb B-2 oncoprotein overexpression, early recurrence, and cancer death in non-small cell lung cancer. Am J Respir Crit Care Med 155:1419
Zelen M (1973) Keynote address on biostatistics and data retrieval. Cancer Chemother Rep 4:21
Zimmerman PV, Bint MH, Hawson GAT et al (1987) Ploidy as a prognostic determinant in surgically treated lung cancer. Lancet 2:530
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2004 Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
Quejada, M.I., Albain, K.S. (2004). Prognostic Factors in Non-Small Cell Lung Cancer. In: Sculier, JP., Fry, W.A. (eds) Malignant Tumors of the Lung. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-18698-1_37
Download citation
DOI: https://doi.org/10.1007/978-3-642-18698-1_37
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-62253-3
Online ISBN: 978-3-642-18698-1
eBook Packages: Springer Book Archive